Tadalafil Enhances the Inhibitory Effects of Tamsulosin on Neurogenic Contractions of Human Prostate and Bladder Neck

Journal of Sexual Medicine

Volumn 9, Issue 9, 2012, Pages 2293-2306

  Angulo, Javier ^a   Cuevas, Pedro ^a   Fernández, Argentina ^a   La Fuente, José M ^b   Allona, Antonio ^c   Moncada, Ignacio ^d   Sáenz de Tejada, Iñigo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^c HOSPITAL RUBER INTERNACIONAL   (Spain)

^d HOSPITAL LA ZARZUELA   (Spain)

Author keywords

Benign Prostatic Hyperplasia; Erectile Dysfunction; Lower Urinary Tract Symptoms; Phosphodiesterase Type 5 Inhibitors; Tadalafil; Tamsulosin

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; TADALAFIL; TAMSULOSIN;

ADULT; AGED; ARTICLE; BLADDER CONTRACTION; BLADDER NECK; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTROSTIMULATION; HUMAN; HUMAN TISSUE; MALE; NEUROGENIC BLADDER; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; SMOOTH MUSCLE TONE;

EID: 84865750148     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02821.x     Document Type: Article

References (45)

1. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49.
2. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2010. In press.
3. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7.
4. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008;180:1228-34.
5. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502-7.
6. Ückert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006;49:740-5.
7. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7:59-69.
8. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-29.
9. Kedia GT, Ückert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms. World J Urol 2008;26:603-9.
10. Hedlund P, Ekstrom P, Larsson B, Alm P, Andersson KE. Heme oxygenase and NO-synthase in the human prostate-Relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 1997;63:115-26.
11. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, Chang TS. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995;45:435-9.
12. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997;33:1-8.
13. Dixon JS, Jen PY, Gosling JA. A double-label immunohistochemical study of intramural ganglia from the human male urinary bladder neck. J Anat 1997;190:125-34.
14. Andersson KE, Wein J. Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56:581-631.
15. Angulo J, González-Corrochano R, Cuevas P, Fernández A, La Fuente JM, Rolo F, Allona A, Sáenz de Tejada I. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med 2010;7:758-68.
16. Stacey P, Rulten S, Dapling A, Phillips SC. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998;247:249-54.
17. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746-60.
18. Ückert S, Sormes M, Kedia G, Scheller F, Knapp WH, Jonas U, Stief CG. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008;71:526-30.
19. Zhang X, Zang N, Wei Y, Yin J, Teng R, Seftel A, Disanto ME. Testosterone regulates smooth muscle contractile pathways in the rat prostate: Emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab 2012;302:E243-53.
20. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-63.
21. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171:1029-35.
22. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996;16:21-8.
23. James S, Chappel CR, Phillips ML, Greengrass PM, Davey MJ, Turner-Warwick RT, Milroy EJG, Burnstock G. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 1989;142:438-44.
24. Hedlund H, Andersson KE, Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985;134:1291-8.
25. 2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147:S88-119.
26. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, Denoux Y, Faix A, Leriche A, Wayman C, Alexandre L, Giuliano F. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009;6:836-47.
27. Oger S, Behr-Roussel D, Gorny D, Lebret T, Denoux Y, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 2010;57:699-707.
28. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006;61:280-8.
29. Eli Lilly & Company. Cialis: EPAR-Product information. 2011. Available online at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000436/WC500026318.pdf (accessed May 25, 2012).
30. Schilit S, Benzeroual KE. Silodosin: A selective α1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther 2009;31:2489-502.
31. Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S, Tsujimoto G. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: Characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 1995;48:250-8.
32. Caremel R, Oger-Roussel S, Behr-Roussel D, Grise P, Giuliano FA. Nitric oxide/cyclic guanosine monophosphate signaling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 2010;58:616-25.
33. Behr-Roussel D, Oger S, Caisey S, Sandner P, Bernabé J, Alexadre L, Giuliano F. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol 2011;59:272-9.
34. Yoshida M, Akaike T, Inadome A, Takahashi W, Seshita H, Yono M, Goto S, Maeda H, Ueda S. The possible effect of nitric oxide on relaxation and noradrenaline release in the isolated rabbit urethra. Eur J Pharmacol 1998;357:213-9.
35. Seshita H, Yoshida M, Takahashi W, Inadome A, Yono M, Miyamoto Y, Murakami S, Ueda S. Prejunctional alpha-adrenoceptors regulate nitrergic neurotransmission in the rabbit urethra. Eur J Pharmacol 2000;400:271-8.
36. Strittmatter F, Gratzke C, Weinhold P, Steib CJ, Hartmann AC, Schlenker B, Andersson KE, Hedlund P, Stief CG, Hennenberg M. Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol 2011;650:650-5.
37. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004;309:1148-53.
38. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009;6:1594-608.
39. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995;45:440-6.
40. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170-8.
41. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717-23.
42. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009;21:122-8.
43. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010;28:17-22.
44. Oztürk MI, Kalkan S, Koca O, Güneş M, Akyüz M, Karaman MI. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia 2011;44(Suppl 1):791-5.
45. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-25.